Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor Clinical Trial
Official title:
A Pilot Study of Whole-body MRI-guided Intensity Modulated Radiation Therapy Combined With Systemic Chemotherapy Followed by High-Dose Chemotherapy With Busulfan, Melphalan and Topotecan and Stem Cell Rescue in Patients With Poor Risk Ewing's Sarcoma
Verified date | January 2015 |
Source | City of Hope Medical Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Federal Government |
Study type | Interventional |
This pilot clinical trial studies whole-body radiation therapy, systemic chemotherapy, and high-dose chemotherapy followed by stem cell rescue in treating patients with poor-risk Ewing sarcoma. Giving chemotherapy and radiation therapy before a peripheral blood stem cell or bone marrow transplant stops the growth of tumor cells by stopping them from dividing or killing them. After treatment, stem cells are collected from the patient's blood and stored. More chemotherapy is given to prepare the bone marrow for stem cell transplant. The stem cells are then returned to the patient to replace the blood-forming cells that were destroyed by the chemotherapy
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | |
Est. primary completion date | March 2018 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 6 Months to 40 Years |
Eligibility |
Inclusion Criteria: - Patients with relapsed Ewing's sarcoma or primitive neuroectodermal tumor (PNET) with bony/soft tissue metastasis who achieved at least partial response (PR) to chemotherapy, surgery or radiotherapy - Newly diagnosed patients with metastatic disease to the bones: patients with metastatic Ewing's or metastatic PNET who achieved at least partial response (PR) to chemotherapy, surgery or radiotherapy are eligible - Ewing's sarcoma/PNET histology confirmed by Anatomic Pathology Department; histological confirmation of relapse is highly recommended but not mandatory - Patients must have documented at least partial response (PR) to previous therapy regimens; previous modalities may include surgery, chemotherapy, or radiation therapy; radiation must not include lung fields; only patients in CR or PR at the primary site will be eligible - Patients must have metastatic/recurrent disease identified by WB-MRI at the time of study entry; intensity-modulated radiation therapy (IMRT) can be delivered per protocol guidelines to at least one but not more than five primary/metastatic sites - Patients must have Karnofsky performance status > 60% OR Lansky performance status > 50% for patients younger than 16 years old - Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for six months following duration of study participation; should a woman become pregnant or suspect that she is pregnant while participating on the trial, she should inform her treating physician immediately - Adequate number of autologous stem cells collected and cryopreserved prior to starting the study treatment - Creatinine clearance (12 or 24 hour urine collection) or glomerular filtration rate (GFR) > 60 ml/min/1.73 m^2 - Ejection fraction > 50% by echocardiogram or multiple gated acquisition (MUGA) - Bilirubin < 2 x upper limit of normal - Serum glutamic oxalo-acetic transaminase (SGOT) and serum glutamate pyruvate transaminase (SGPT) < 5 x upper limit of normal - Platelet count > 50,000/ul - Absolute granulocyte count >= 750/ul - Forced expiratory volume in one second (FEV1) > 2 liters adults (older than 16 years) - Room air arterial oxygen pressure (PaO2) > 70 mm Hg adults (older than 16 years) - Room air partial pressure of carbon dioxide (PaCO2) < 42 mm Hg adults (older than 16 years) - Diffusion capacity of carbon monoxide (DLCO) > 50% predicted - If unable to cooperate with pulmonary function testing due to young age, then pulse oximetry >= 94% children (younger than 16 years) - Pretreatment tests must have been performed within 4 weeks prior to initiation of protocol treatment - No other medical and/or psychosocial problems which, in the opinion of the primary physician or principal investigator, would place the patient at unacceptable risk from this regimen - Greater than 2 week period of recovery from prior modality used to control primary or recurrent site - All subjects or their legal guardians must have the ability to understand and the willingness to sign a written informed consent Exclusion Criteria: - Patients should not have any uncontrolled illness including ongoing or active infection - Patients may not be receiving any other investigational agents, concurrent biological agents, or chemotherapy - Patients must not have received prior chemotherapy or radiation within 2 weeks before study enrollment, and those who have not recovered from the adverse events due to agents administered more than 2 weeks earlier are excluded - Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated on this study - Patients with other active malignancies are ineligible for this study - Patients with prior treatment with myeloablative therapy are excluded - Karnofsky performance status < 60% or Lansky performance status < 50% for patients younger than 16 years old - Patients who require irradiation to more than 5 disease sites are excluded - Subjects who, in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study |
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | City of Hope Medical Center | Duarte | California |
Lead Sponsor | Collaborator |
---|---|
City of Hope Medical Center | National Cancer Institute (NCI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percentage of patients who experience grade 4-5 non-hematologic toxicities assessed by National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 | Toxicities will be summarized as type, severity, date of onset, duration, reversibility, and attribution. | Up to day 100 of Block II | Yes |
Secondary | Overall response rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) | Objective tumor response for all patients will be summarized, including the number and percent responding. | Up to 5 years | No |
Secondary | Progression-free survival (PFS) | PFS will be estimated using the Kaplan-Meier product-limit method; 95% confidence intervals (CIs) will be calculated using the logit transformation and the Greenwood variance estimate. | Time from stem cell infusion to the first observation of disease progression or death from any cause, whichever occurs first, assessed up to 5 years | No |
Secondary | Overall survival (OS) | OS will be estimated using the Kaplan-Meier product-limit method; 95% confidence intervals (CIs) will be calculated using the logit transformation and the Greenwood variance estimate. | Time from stem cell infusion to death from any cause, assessed up to 5 years | No |
Secondary | Non-relapse mortality (NRM) | Cumulative relapse incidence will be estimated treating non-relapse related death events as competing risks and, conversely, NRM will be calculated controlling for relapse as a competing risk. Cumulative incidence of NRM and relapse-related mortality will be calculated using the method of Goole et al. Cumulative incidence differences will be assessed by Gray's test. | Time from stem cell infusion to death event where the cause of death is not attributable to the underlying disease, assessed up to 5 years | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00093821 -
Tanespimycin in Treating Young Patients With Recurrent or Refractory Leukemia or Solid Tumors
|
Phase 1 | |
Active, not recruiting |
NCT03233204 -
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
|
Phase 2 | |
Completed |
NCT00091182 -
Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment
|
Phase 2 | |
Completed |
NCT00004078 -
Irinotecan in Treating Children With Refractory Solid Tumors
|
Phase 2 | |
Completed |
NCT00004241 -
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma
|
Phase 1 | |
Completed |
NCT00030667 -
Imatinib Mesylate in Treating Patients With Relapsed or Refractory Solid Tumors of Childhood
|
Phase 2 | |
Completed |
NCT02116777 -
Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies
|
Phase 1/Phase 2 | |
Completed |
NCT02304458 -
Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas
|
Phase 1/Phase 2 | |
Completed |
NCT00101270 -
Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas
|
Phase 1 | |
Active, not recruiting |
NCT03210714 -
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
|
Phase 2 | |
Withdrawn |
NCT02011126 -
Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid Tumors
|
Phase 2 | |
Completed |
NCT00536601 -
High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors
|
N/A | |
Completed |
NCT01154452 -
Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma
|
Phase 1/Phase 2 | |
Completed |
NCT00330421 -
Sorafenib in Treating Patients With Soft Tissue Sarcomas (Extremity Sarcoma Closed to Entry as of 5/30/07)
|
Phase 2 | |
Completed |
NCT01614795 -
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
|
Phase 2 | |
Completed |
NCT00609141 -
IMC-A12 in Treating Young Patients With Relapsed or Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor or Other Solid Tumor
|
Phase 1 | |
Active, not recruiting |
NCT00112463 -
Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma
|
Phase 2 | |
Completed |
NCT00048984 -
Diagnostic Study of Tumor Characteristics in Patients With Ewing's Sarcoma
|
N/A | |
Completed |
NCT00899990 -
Collecting and Storing Biological Samples From Patients With Ewing Sarcoma
|
||
Active, not recruiting |
NCT00638898 -
Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor
|
Phase 1 |